PhRMA drums out 22 mem­bers who didn’t make the cut as ma­jor league R&D play­ers


The shake­out at PhRMA is over.

Af­ter be­ing swept up in­to the con­tro­ver­sy that sur­round­ed a cou­ple of its top mem­bers with a no­to­ri­ous­ly itchy trig­ger fin­ger for sky high prices on some unim­pres­sive ther­a­pies, the in­dus­try lob­by­ing group has now com­plet­ed its re­view of their mem­ber­ship rules, com­ing up with some cri­te­ria on who can qual­i­fy for the club.

In a state­ment out to­day, PhRMA notes that mem­bers will have to de­vote at least 10% of their rev­enue to R&D with a min­i­mum re­search bud­get of $200 mil­lion a year — and they have to have main­tained that track record over the last three years.

I’ve al­ready re­port­ed that Marathon and Mallinck­rodt, two com­pa­nies that have found them­selves in the thick of the fight­ing over what they charge for drugs and how they have ben­e­fit­ed from a mo­nop­oly, bowed out ahead of the change-up. Marathon is even wind­ing down op­er­a­tions, as End­points News first re­port­ed.

There are a to­tal of 22 full and as­so­ciate mem­bers who didn’t make the cut on the new R&D cri­te­ria, in­clud­ing the whole tier of 15 biotechs in the as­so­ciate cat­e­go­ry, which is be­ing elim­i­nat­ed.

Joaquin Du­a­to (Im­age: End­points News)

“By putting in place new mem­ber­ship cri­te­ria, the board is send­ing a clear mes­sage that be­ing a mem­ber of PhRMA means be­ing com­mit­ted to do­ing the time-in­ten­sive, sci­en­tif­i­cal­ly sound re­search it takes to bring bold new ad­vances in treat­ments and cures to pa­tients,” said Joaquin Du­a­to, PhRMA board chair­man and world­wide chair­man, phar­ma­ceu­ti­cals, John­son & John­son.

J&J is one of a group of Phar­ma gi­ants that typ­i­cal­ly spend about 15% or more on R&D, with­out any in­di­ca­tion that will shrink any­time soon. Some of the ma­jors go much high­er than that.

The as­so­ciate mem­bers who got cut in­clude Bio­Marin $BM­RN, which is think­ing of ap­ply­ing as a reg­u­lar mem­ber. The com­pa­ny eas­i­ly qual­i­fies un­der the new rules.

A spokesper­son told me:

We are sup­port­ive of PhRMA’s ef­forts on be­half of the phar­ma­ceu­ti­cal in­dus­try.  Bio­Marin was pre­vi­ous­ly a mem­ber of PhRMA as a “Re­search As­so­ci­ate Mem­ber.” PhRMA has dis­con­tin­ued the “Re­search As­so­ci­ate” mem­ber­ship cat­e­go­ry, and at this time, Bio­Marin is not a mem­ber of PhRMA. As out­lined by PhRMA, Bio­Marin meets the new cri­te­ria for full mem­ber­ship. Bio­Marin is now con­sid­er­ing whether to seek full Mem­ber­ship sta­tus from the PhRMA Board. Bio­Marin in­vest­ed more than $600 mil­lion in Re­search and De­vel­op­ment in 2016, which is about 60% or our rev­enues. Bio­Marin is al­so a mem­ber of BIO.

PhRMA CEO Stephen Ubl launched a PR cam­paign at the be­gin­ning of the year to try and re­form the in­dus­try’s tat­tered pub­lic im­age. Now all of its mem­bers can be ex­pect­ed to play the role of am­bas­sadors of ma­jor league drug in­no­va­tion — or try to.

Here’s the list of com­pa­nies who no longer qual­i­fy for mem­ber­ship in Du­a­to’s peer group.


Mem­bers

AM­AG Phar­ma­ceu­ti­cals
Hori­zon Phar­ma
Jazz Phar­ma­ceu­ti­cals
Lea­di­ant Bio­sciences
Mallinck­rodt Phar­ma­ceu­ti­cals
Orex­i­gen Ther­a­peu­tics
The Med­i­cines Com­pa­ny

As­so­ci­ate Mem­bers

ACA­DIA Phar­ma­ceu­ti­cals
Aerie Phar­ma­ceu­ti­cals
Avanir Phar­ma­ceu­ti­cals
Bio­Marin Phar­ma­ceu­ti­cal
CSL Behring
Es­pe­ri­on Ther­a­peu­tics
Fer­ring Phar­ma­ceu­ti­cals
Gri­fols USA
Ipsen Bio­phar­ma­ceu­ti­cals
Marathon Phar­ma­ceu­ti­cals
Sh­iono­gi Inc.
Su­cam­po Phar­ma­ceu­ti­cals
Ther­a­vance Bio­phar­ma
Vi­for Phar­ma
VIVUS, Inc.

MedTech clinical trials require a unique regulatory and study design approach and so engaging a highly experienced CRO to ensure compliance and accurate data across all stages is critical to development milestones.

In­no­v­a­tive MedTech De­mands Spe­cial­ist Clin­i­cal Tri­al Reg­u­la­to­ry Af­fairs and De­sign

Avance Clinical is the Australian CRO for international biotechs providing world-class clinical research services with FDA-accepted data across all phases. With Avance Clinical, biotech companies can leverage Australia’s supportive clinical trials environment which includes no IND requirement plus a 43.5% Government incentive rebate on clinical spend. The CRO has been delivering clinical drug development services for international biotechs for FDA and EMA regulatory approval for the past 24 years. The company has been recognized for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award and a finalist in Informa Pharma’s Best CRO award for 2022.

Gold for adults, sil­ver for in­fants: Pfiz­er's Pre­vnar 2.0 head­ed to FDA months af­ter Mer­ck­'s green light

Pfizer was first to the finish line for the next-gen pneumococcal vaccine in adults, but Merck beat its rival with a jab for children in June.

Now, two months after Merck’s 15-valent Vaxneuvance won the FDA stamp of approval for kids, Pfizer is out with some late-stage data on its 20-valent shot for infants.

Known as Prevnar 20 for adults, Pfizer’s 20vPnC will head to the FDA by the end of this year for an approval request in infants, the Big Pharma said Friday morning. Discussions with the FDA will occur first and more late-stage pediatric trials are expected to read out soon, informing the regulatory pathway in other countries and regions.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,700+ biopharma pros reading Endpoints daily — and it's free.

Senate Finance Committee Chair Ron Wyden (D-OR) (Francis Chung/E&E News/POLITICO via AP Images)

Sen­ate Fi­nance Chair con­tin­ues his in­ves­ti­ga­tion in­to phar­ma tax­es with re­quests for Am­gen

Amgen is the latest pharma company to appear on the radar of Senate Finance Committee Chair Ron Wyden (D-OR), who is investigating the way pharma companies are using subsidiaries in low- or zero-tax countries to lower their tax bills.

Like its peers Merck, AbbVie and Bristol Myers Squibb, Wyden notes how Amgen uses its Puerto Rico operations to consistently pay tax rates that are substantially lower than the U.S. corporate tax rate of 21%, with an effective tax rate of 10.7% in 2020 and 12.1% in 2021.

FDA ap­proves sec­ond in­di­ca­tion for As­traZeneca and Dai­ichi's En­her­tu in less than a week

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu scored its second approval in less than a week, this time for a subset of lung cancer patients.

Enhertu received accelerated approval on Thursday to treat adults with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, and who have already received a prior systemic therapy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,700+ biopharma pros reading Endpoints daily — and it's free.

J&J to re­move talc prod­ucts from shelves world­wide, re­plac­ing with corn­starch-based port­fo­lio

After controversially spinning out its talc liabilities and filing for bankruptcy in an attempt to settle 38,000 lawsuits, Johnson & Johnson is now changing up the formula for its baby powder products.

J&J is beginning the transition to an all cornstarch-based baby powder portfolio, the pharma giant announced on Thursday — just months after a federal judge ruled in favor of its “Texas two-step” bankruptcy to settle allegations that its talc products contained asbestos and caused cancer. An appeals court has since agreed to revisit that case.

CSL is gathering its four business units under a unified brand identity strategy (Credit: CSL company site)

CSL brings Se­qirus, Vi­for un­der par­ent um­brel­la brand in iden­ti­ty re­vamp

CSL is gathering its brands under the family name umbrella, renaming its vaccine and newly acquired nephrology specialty businesses with the parent initials.

CSL Seqirus and CSL Vifor join CSL Plasma and CSL Behring as the four now uniformly branded business units of the global biopharma. The Seqirus vaccine division was formed in 2015 with the combination of bioCSL and its purchase of Novartis’ flu vaccine business. CSL picked up Vifor Pharma late last year in an $11.7 billion deal for the nephrology, iron deficiency and cardio-renal drug developer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,700+ biopharma pros reading Endpoints daily — and it's free.

Pharma brands are trying to figure out new ways to better reach patients and doctors, but also measure results. (Credit: Shutterstock)

Do phar­ma TV and so­cial ads work? Phar­ma mar­ket­ing agen­cies adopt­ing new tech so­lu­tions to find out

It’s a timeworn advertising question — is my ad campaign working? In pharma, that can be an especially difficult question to answer in part because of privacy regulations, but also because the brands spend a lot of money on TV commercials where viewers can’t directly click on an ad.

Healthcare marketing services companies like Lasso and CMI Media Group are trying to change that with new measurement methods and partnerships that aim to get closer to patients’ and physicians’ actions.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,700+ biopharma pros reading Endpoints daily — and it's free.

Corey McCann, Pear Therapeutics CEO

Pear Ther­a­peu­tics touts Q2 growth while scal­ing back full-year goals and chop­ping 9% of staff

Pear Therapeutics set some ambitious goals back in March, predicting a five-fold boost in revenue and a surge in new prescriptions for its digital therapeutics. Now the company is scaling back those estimates and chopping 9% of its workforce — an all-too-common occurrence in biotech lately.

CEO Corey McCann unveiled Pear’s Q2 numbers on Thursday, touting a 20% quarter-over-quarter revenue growth totaling $3.3 million. That’s more than double what the company made in Q2 2021, and McCann thinks the team could see a nearly four-fold jump in revenue this year, falling in the range of $14 million to $16 million.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,700+ biopharma pros reading Endpoints daily — and it's free.

Seagen interim CEO Roger Dansey and Daiichi Sankyo CEO Sunao Manabe

Paving the way for Mer­ck­'s buy­out, Seagen los­es ar­bi­tra­tion dis­pute with Dai­ichi over ADC tech

As Seagen awaits a final buyout offer from Merck that could be in the territory of $40 billion, Seagen revealed Friday afternoon that it lost an arbitration dispute with Daiichi Sankyo relating to the companies’ 2008 collaboration around the use of antibody-drug conjugate (ADC) technology.

But that loss likely won’t matter much when it comes to Merck’s deal.

After breaking off its pact with Daiichi in mid-2015, the two companies battled over “linker” tech — a chemical bridge between an ADC’s antibody component and the cytotoxic payload — that Seagen claims Daiichi would improve upon and implement in its current generation of ADCs.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,700+ biopharma pros reading Endpoints daily — and it's free.